Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. (2013)

First Author: Davies C

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/S0140-6736(12)61963-1

PubMed Identifier: 23219286

Publication URI: http://europepmc.org/abstract/MED/23219286

Type: Journal Article/Review

Volume: 381

Parent Publication: Lancet (London, England)

Issue: 9869

ISSN: 0140-6736